NeoGenomics, Inc. (NEO) Income Statement
NEO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNEO revenue and net income
Where NEO's revenue goes
2025Each bar shows an amount and its share of revenue. NEO kept −14.9% of revenue as net income.
NEO profit margins
NEO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +10.1% | +12.6% | +10.4% | +22.0% |
| Gross profit | −2.6% | +14.6% | +8.7% | +20.5% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NEO quarterly EPS vs estimates
NeoGenomics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: October 28, 2026 (estimate $-0.01).
NEO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M | $444.4M | $408.8M | $276.7M | $240.3M | $244.1M |
| Cost of revenue | $444.8M | $370.5M | $347.0M | $321.8M | $297.3M | $258.6M | $212.0M | $149.5M | $138.3M | $133.7M |
| Gross profit | $282.5M | $290.1M | $244.6M | $187.9M | $187.1M | $185.9M | $196.8M | $127.3M | $102.0M | $110.4M |
| Research & development | $37.1M | $31.2M | $27.3M | $30.3M | $21.9M | $8.2M | $8.5M | $3.0M | $3.6M | $4.6M |
| Sales, general & admin | $273.3M | $310.5M | $280.0M | $277.9M | $283.9M | $191.7M | $175.3M | $114.2M | $88.8M | $87.8M |
| Total operating expenses | $348.6M | $382.2M | $352.3M | $345.5M | $305.8M | $199.9M | $183.8M | $117.2M | $99.1M | $95.9M |
| Operating income | −$66.1M | −$92.1M | −$107.7M | −$157.6M | −$118.8M | −$14.0M | $13.0M | $10.0M | $2.9M | $2.6M |
| Interest income | $9.1M | $18.4M | $16.9M | $6.1M | $3.1M | — | $3.7M | $6.2M | $5.5M | $10.0M |
| Interest expense | $3.8M | $6.6M | $6.9M | $7.6M | $8.2M | $7.0M | $3.7M | $6.2M | $5.5M | $10.0M |
| Income before taxes | −$110.3M | −$80.7M | −$97.1M | −$159.3M | −$15.1M | −$14.1M | $3.6M | $3.8M | −$2.6M | −$7.4M |
| Income taxes | −$2.2M | −$1.9M | −$9.1M | −$15.1M | −$6.7M | −$18.2M | −$4.4M | $1.2M | −$2.3M | −$1.7M |
| Net income | −$108.0M | −$78.7M | −$88.0M | −$144.2M | −$8.3M | $4.2M | $8.0M | $2.6M | −$396,000 | −$6.1M |
| EBITDA | −$38.7M | −$1.5M | −$17.6M | −$82.3M | $46.5M | $28.7M | $37.6M | $31.8M | $26.6M | $25.4M |
| EPS (diluted) | −$0.08 | −$0.09 | −$0.13 | −$0.56 | −$0.27 | $0.14 | $0.31 | $0.20 | $0.13 | $0.16 |
| Gross margin | 38.8% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 45.2% |
| Operating margin | −9.1% | −13.9% | −18.2% | −30.9% | −24.5% | −3.1% | 3.2% | 3.6% | 1.2% | 1.1% |
| Net margin | −14.9% | −11.9% | −14.9% | −28.3% | −1.7% | 0.9% | 2.0% | 1.0% | −0.2% | −2.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.7M | $186.7M | $190.2M | $187.8M | $181.3M | $168.0M | $172.0M | $167.8M | $164.5M | $156.2M | $155.6M | $152.0M |
| Cost of revenue | $109.8M | $105.8M | $114.5M | $107.4M | $104.1M | $94.8M | $94.7M | $92.9M | $92.0M | $90.8M | $88.0M | $89.6M |
| Gross profit | $91.9M | $80.9M | $75.7M | $80.4M | $77.3M | $73.2M | $77.3M | $74.9M | $72.5M | $65.5M | $67.6M | $62.3M |
| Research & development | $10.8M | $9.5M | $9.2M | $8.7M | $9.0M | $10.2M | $8.0M | $7.7M | $7.9M | $7.6M | $7.1M | $5.3M |
| Sales, general & admin | $90.9M | $89.6M | $63.5M | $91.7M | $95.8M | $87.9M | $86.0M | $87.4M | $85.0M | $86.0M | $77.8M | $79.1M |
| Total operating expenses | $101.6M | $99.1M | $86.9M | $107.5M | $124.9M | $101.1M | $95.7M | $96.1M | $94.4M | $96.0M | $86.2M | $86.5M |
| Operating income | −$9.8M | −$18.2M | −$11.1M | −$27.0M | −$47.6M | −$27.8M | −$18.4M | −$21.2M | −$21.9M | −$30.6M | −$18.6M | −$24.2M |
| Interest income | $1.2M | $1.3M | $1.5M | $1.6M | $2.3M | $3.7M | $4.3M | $4.7M | $4.6M | $4.8M | $10.1M | $2.8M |
| Interest expense | $781,000 | $598,000 | $599,000 | $603,000 | $933,000 | $1.6M | $1.6M | $1.6M | $1.7M | $1.7M | $1.7M | $1.7M |
| Income before taxes | $1.8M | −$17.6M | −$12.4M | −$26.4M | −$45.8M | −$25.7M | −$16.1M | −$17.8M | −$19.0M | −$27.7M | −$15.3M | −$21.5M |
| Income taxes | −$412,000 | −$472,000 | −$2.5M | $740,000 | −$724,000 | $266,000 | −$804,000 | −$150,000 | −$375,000 | −$620,000 | −$960,000 | −$2.9M |
| Net income | $2.2M | −$17.1M | −$9.9M | −$27.1M | −$45.1M | −$25.9M | −$15.3M | −$17.7M | −$18.6M | −$27.1M | −$14.3M | −$18.5M |
| EBITDA | $18.8M | −$567,000 | $4.6M | −$10.0M | −$27.6M | −$6.3M | $3.7M | $1.8M | $756,000 | −$7.7M | $4.8M | −$1.6M |
| EPS (diluted) | −$0.01 | $0.01 | $0.06 | $0.03 | $0.03 | −$0.20 | $0.04 | −$0.14 | $0.03 | −$0.02 | $0.03 | −$0.02 |
| Gross margin | 45.6% | 43.3% | 39.8% | 42.8% | 42.6% | 43.6% | 44.9% | 44.6% | 44.1% | 41.9% | 43.5% | 41.0% |
| Operating margin | −4.8% | −9.8% | −5.9% | −14.4% | −26.3% | −16.6% | −10.7% | −12.6% | −13.3% | −19.6% | −11.9% | −15.9% |
| Net margin | 1.1% | −9.2% | −5.2% | −14.4% | −24.9% | −15.4% | −8.9% | −10.5% | −11.3% | −17.3% | −9.2% | −12.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NEO's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NEO financial results
In fiscal year 2025 (ended December 31, 2025), NeoGenomics reported revenue of $727.3 million, up 10.1% from the year before. It had a net loss of $108.0 million, a net profit margin of −14.9%. Diluted earnings per share came to −$0.08. Over five years revenue grew at an average rate of 10.4% a year.
See the NEO stock overview for the latest quote and news, or the NEO chart for price history and technical indicators.
NEO income statement FAQ
What is NeoGenomics's annual revenue?
NeoGenomics reported total revenue of $727.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 10.1% from $660.6 million the previous year.
Is NeoGenomics profitable?
No. NeoGenomics reported a net loss of $108.0 million in fiscal 2025, a net profit margin of −14.9%; its operating margin was −9.1%.
What is NeoGenomics's gross margin?
NeoGenomics's gross margin was 38.8% in fiscal 2025: for every $100 of revenue, NeoGenomics kept $39 after the direct cost of its products and services.
How much does NeoGenomics spend on research and development?
NeoGenomics spent $37.1 million on research and development in fiscal 2025, 5.1% of revenue.
How fast is NeoGenomics growing?
Revenue grew 10.4% a year on average over the last five fiscal years, from $444.4 million to $727.3 million.
What are NeoGenomics's earnings per share?
NeoGenomics earned $-0.08 per diluted share in fiscal 2025, compared with $-0.09 a year earlier.
When will NeoGenomics report its next earnings?
NeoGenomics is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes.
When does NeoGenomics's fiscal year end?
NeoGenomics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.